EXL 0.00% 0.5¢ elixinol wellness limited

Issuer Elixinol Global Limited (ASX:EXL; OTCQX:ELLXF) (“EXL”,...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 497 Posts.
    lightbulb Created with Sketch. 27
    Issuer
    Elixinol Global Limited (ASX:EXL; OTCQX:ELLXF) (“EXL”, “Elixinol Global” or the “Company”
    Transaction
    Placement of approximately 21.6 million new fully paid ordinary shares (“New Shares” to raise approximately A$40.0 million (the “Placement”
    Lead Manager
    Bell Potter Securities Limited (“Bell Potter” or the “Lead Manager”
    Last Close Price
    A$2.15
    Offer Price
    A$1.85 (14.0% discount to last close, 6.7% discount to the 5 day VWAP)
    Shares on Issue
    102,875,981
    Market Cap. (at Last Close)
    A$221,183,359 (at last close)
    Book Close1
    9.00am (Sydney Time) Friday, 28 September 2018
    Note: (1) The Company and Lead Manager reserve the right to close the book early and without notice
    Company Description
    Company Overview
    Elixinol Global through its businesses has a global presence in the cannabis industry including hemp-derived CBD dietary supplements, food and wellness products, as well as the cultivation and manufacture of medicinal cannabis products. Elixinol Global’s businesses include:
     Elixinol USA: which was founded in 2014, is a manufacturer and global distributor of industrial hemp based dietary supplement and skincare products, with operations based out of Colorado, USA;
     Hemp Foods Australia: which was founded in 1999, is a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products;
     Elixinol Australia: which was founded in 2014 to participate in the emerging Australian medicinal cannabis market and submitted licence applications for cultivation and manufacture to the Office of Drug Control in early 2018. These applications are currently pending approval.
    Investment Highlights


    Offer Structure
    Transaction
    Placement of New Shares at A$1.85 per share. The Placement is approximately 21.0% of the issued capital and will be conducted under the 15% placement capacity of the Company in accordance with ASX L.R 7.1 and additional 10% placement capacity of the Company in accordance with ASX LR.7.1A.
    New Shares under the Placement will rank pari passu with existing ordinary shares.
    Use of Proceeds
    Use of proceeds USA
    Includes increased sales & marketing, stage 3 production facility and potential acquisition opportunities
    Europe
    Sales and marketing expansion
    General working capital Total
    Amount (A$) A$25.6m
    A$2.0m
    A$12.4m
    A$40.0m

    Pricing
    Offer Price
    Last close
    5 day VWAP 10 day VWAP
    Price per share
    A$1.85
    Offer Price discount to Last Close and VWAP
    A$2.15
    A$1.983 6.7% A$1.975 6.3%
    14.0%
    Capital Structure
    Capital Structure

    Shares

    Existing shares on issue
    102,875,981
    Placement shares issued

    21,621,622
    Shares on issue post Offer
    124,497,603
 
watchlist Created with Sketch. Add EXL (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.000(0.00%)
Mkt cap ! $6.605M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $1.605K 321.0K

Buyers (Bids)

No. Vol. Price($)
7 6265944 0.5¢
 

Sellers (Offers)

Price($) Vol. No.
0.6¢ 14532474 10
View Market Depth
Last trade - 15.57pm 25/11/2024 (20 minute delay) ?
EXL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.